{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T13:28:41Z","timestamp":1743082121731,"version":"3.40.3"},"publisher-location":"Cham","reference-count":85,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031631177"},{"type":"electronic","value":"9783031631184"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/82_2022_252","type":"book-chapter","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:21:29Z","timestamp":1648228889000},"page":"229-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in Developing a Controlled Human Tuberculosis Challenge Model"],"prefix":"10.1007","author":[{"given":"Susan","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"issue":"4","key":"252_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1164\/rccm.201208-1352OC","volume":"187","author":"IM Adetifa","year":"2013","unstructured":"Adetifa IM et al (2013) Interferon-\u03b3 ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am J Respir Crit Care Med 187(4):439\u2013445","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"252_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"P Andersen","year":"2005","unstructured":"Andersen P, Doherty TM (2005) The success and failure of BCG\u2014implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3(8):656\u2013662","journal-title":"Nat Rev Microbiol"},{"key":"252_CR3","doi-asserted-by":"crossref","unstructured":"Arbues A et al (2013) Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 31(42):4867\u20134873","DOI":"10.1016\/j.vaccine.2013.07.051"},{"issue":"1","key":"252_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4049\/jimmunol.1100823","volume":"187","author":"J Arcos","year":"2011","unstructured":"Arcos J et al (2011) Human lung hydrolases delineate Mycobacterium tuberculosis-macrophage interactions and the capacity to control infection. J Immunol 187(1):372\u2013381","journal-title":"J Immunol"},{"issue":"6","key":"252_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/infdis\/jiv146","volume":"212","author":"J Arcos","year":"2015","unstructured":"Arcos J et al (2015) Lung mucosa lining fluid modification of Mycobacterium tuberculosis to reprogram human neutrophil killing mechanisms. J Infect Dis 212(6):948\u2013958","journal-title":"J Infect Dis"},{"issue":"5","key":"252_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/mi.2016.115","volume":"10","author":"J Arcos","year":"2017","unstructured":"Arcos J et al (2017) Mycobacterium tuberculosis cell wall released fragments by the action of the human lung mucosa modulate macrophages to control infection in an IL-10-dependent manner. Mucosal Immunol 10(5):1248\u20131258","journal-title":"Mucosal Immunol"},{"issue":"12","key":"252_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrmicro2236","volume":"7","author":"CE Barry 3rd","year":"2009","unstructured":"Barry CE 3rd et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845\u2013855","journal-title":"Nat Rev Microbiol"},{"issue":"9151","key":"252_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(98)03406-0","volume":"353","author":"MA Behr","year":"1999","unstructured":"Behr MA et al (1999a) Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353(9151):444\u2013449","journal-title":"Lancet"},{"issue":"5419","key":"252_CR9","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"MA Behr","year":"1999","unstructured":"Behr MA et al (1999b) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284(5419):1520\u20131523","journal-title":"Science"},{"key":"252_CR10","doi-asserted-by":"crossref","unstructured":"Bekker LG et al (2020) A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine 21:100313","DOI":"10.1016\/j.eclinm.2020.100313"},{"issue":"9315","key":"252_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","volume":"359","author":"GF Black","year":"2002","unstructured":"Black GF et al (2002) BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359(9315):1393\u20131401","journal-title":"Lancet"},{"issue":"2","key":"252_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","volume":"70","author":"L Brandt","year":"2002","unstructured":"Brandt L et al (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70(2):672\u2013678","journal-title":"Infect Immun"},{"issue":"11","key":"252_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/cid\/ciw145","volume":"62","author":"WH Chen","year":"2016","unstructured":"Chen WH et al (2016) Single-dose Live Oral Cholera Vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor. Clin Infect Dis 62(11):1329\u20131335","journal-title":"Clin Infect Dis"},{"issue":"8379","key":"252_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(84)92222-0","volume":"1","author":"ML Clements","year":"1984","unstructured":"Clements ML, Betts RF, Murphy BR (1984) Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A\/Washington\/80 (H3N2) wild-type virus infection. Lancet 1(8379):705\u2013708","journal-title":"Lancet"},{"issue":"9","key":"252_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz GA et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271(9):698\u2013702","journal-title":"JAMA"},{"issue":"6685","key":"252_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole ST et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685):537\u2013544","journal-title":"Nature"},{"issue":"2","key":"252_CR17","first-page":"275","volume":"55","author":"CL Cusumano","year":"1975","unstructured":"Cusumano CL, Jernigan JA, Waldman RH (1975) Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study. J Natl Cancer Inst 55(2):275\u2013279","journal-title":"J Natl Cancer Inst"},{"key":"252_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-019-0113-9","volume":"4","author":"PA Darrah","year":"2019","unstructured":"Darrah PA et al (2019) Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. NPJ Vaccines 4:21","journal-title":"NPJ Vaccines"},{"issue":"10","key":"252_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1164\/rccm.201908-1580OC","volume":"201","author":"M Davids","year":"2020","unstructured":"Davids M et al (2020) A human lung challenge model to evaluate the safety and immunogenicity of PPD and live Bacillus Calmette-Gu\u00e9rin. Am J Respir Crit Care Med 201(10):1277\u20131291","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"252_CR20","first-page":"399","volume":"7","author":"I Dourado","year":"2003","unstructured":"Dourado I et al (2003) Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis 7(4):399\u2013402","journal-title":"Int J Tuberc Lung Dis"},{"key":"252_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2334-10-57","volume":"10","author":"AM Dyrhol-Riise","year":"2010","unstructured":"Dyrhol-Riise AM et al (2010) Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 10:57\u201357","journal-title":"BMC Infect Dis"},{"issue":"10","key":"252_CR22","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.4049\/jimmunol.177.10.7086","volume":"177","author":"CG Feng","year":"2006","unstructured":"Feng CG et al (2006) NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 177(10):7086\u20137093","journal-title":"J Immunol"},{"issue":"4","key":"252_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/1097-0142(197504)35:4<1088::AID-CNCR2820350411>3.0.CO;2-2","volume":"35","author":"FB Garner","year":"1975","unstructured":"Garner FB et al (1975) Aerosol BCG treatment of carcinoma metastatic to the lung: a phase I study. Cancer 35(4):1088\u20131094","journal-title":"Cancer"},{"issue":"1","key":"252_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12271","volume":"264","author":"MC Gold","year":"2015","unstructured":"Gold MC, Napier RJ, Lewinsohn DM (2015) MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol Rev 264(1):154\u2013166","journal-title":"Immunol Rev"},{"issue":"8","key":"252_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/infdis\/jit647","volume":"209","author":"SA Harris","year":"2014","unstructured":"Harris SA et al (2014) Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J Infect Dis 209(8):1259\u20131268","journal-title":"J Infect Dis"},{"key":"252_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tube.2017.11.006","volume":"108","author":"SA Harris","year":"2018","unstructured":"Harris SA et al (2018) Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines. Tuberculosis (edinb) 108:99\u2013105","journal-title":"Tuberculosis (edinb)"},{"issue":"6082","key":"252_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/bmj.2.6082.293","volume":"2","author":"PD Hart","year":"1977","unstructured":"Hart PD, Sutherland I (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 2(6082):293\u2013295","journal-title":"Br Med J"},{"issue":"4","key":"252_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/thx.2003.011759","volume":"59","author":"E Hern\u00e1ndez-Gardu\u00f1o","year":"2004","unstructured":"Hern\u00e1ndez-Gardu\u00f1o E et al (2004) Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 59(4):286\u2013290","journal-title":"Thorax"},{"key":"252_CR29","doi-asserted-by":"crossref","unstructured":"Hoang T et al (2013) ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 8(12):e80579","DOI":"10.1371\/journal.pone.0080579"},{"key":"252_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12936-015-0671-x","volume":"14","author":"SH Hodgson","year":"2015","unstructured":"Hodgson SH et al (2015) Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J 14:182\u2013182","journal-title":"Malar J"},{"issue":"1","key":"252_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13063-017-2354-0","volume":"19","author":"J Hussein","year":"2018","unstructured":"Hussein J et al (2018) A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1\/IC31\u00ae in people living in a TB-endemic area. Trials 19(1):24","journal-title":"Trials"},{"issue":"2","key":"252_CR32","first-page":"81","volume":"83","author":"T Inoue","year":"2008","unstructured":"Inoue T, Koyasu H, Hattori S (2008) Transmission of tuberculosis from smear-negative bacillus-positive pulmonary TB patients. Kekkaku 83(2):81\u201385","journal-title":"Kekkaku"},{"issue":"8","key":"252_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bioe.12802","volume":"34","author":"E Jamrozik","year":"2020","unstructured":"Jamrozik E, Selgelid MJ (2020) Ethical issues surrounding controlled human infection challenge studies in endemic low-and middle-income countries. Bioethics 34(8):797\u2013808","journal-title":"Bioethics"},{"issue":"1","key":"252_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12274","volume":"264","author":"LD Jasenosky","year":"2015","unstructured":"Jasenosky LD et al (2015) T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev 264(1):74\u201387","journal-title":"Immunol Rev"},{"issue":"2","key":"252_CR35","doi-asserted-by":"publisher","first-page":"e1000782","DOI":"10.1371\/journal.ppat.1000782","volume":"6","author":"SA Joosten","year":"2010","unstructured":"Joosten SA et al (2010) Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 6(2):e1000782\u2013e1000782","journal-title":"PLoS Pathog"},{"issue":"3","key":"252_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester KE et al (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200(3):337\u2013346","journal-title":"J Infect Dis"},{"issue":"7","key":"252_CR37","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1128\/CVI.00092-15","volume":"22","author":"N Lenz","year":"2015","unstructured":"Lenz N et al (2015) Antiviral innate immune activation in HIV-infected adults negatively affects H1\/IC31-induced vaccine-specific memory CD4+ T cells. Clin Vaccine Immunol 22(7):688\u2013696","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"252_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1086\/345862","volume":"187","author":"KN Lewis","year":"2003","unstructured":"Lewis KN et al (2003) Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Gu\u00e9rin attenuation. J Infect Dis 187(1):117\u2013123","journal-title":"J Infect Dis"},{"issue":"12","key":"252_CR39","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/cmi.2017.88","volume":"14","author":"CH Liu","year":"2017","unstructured":"Liu CH, Liu H, Ge B (2017) Innate immunity in tuberculosis: host defense versus pathogen evasion. Cell Mol Immunol 14(12):963\u2013975","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"252_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","volume":"48","author":"JB Lu","year":"2015","unstructured":"Lu JB et al (2015) Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect 48(6):597\u2013603","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"252_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu LL et al (2016) A functional role for antibodies in tuberculosis. Cell 167(2):433-443.e14","journal-title":"Cell"},{"issue":"33","key":"252_CR42","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","volume":"33","author":"AK Luabeya","year":"2015","unstructured":"Luabeya AK et al (2015) First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 33(33):4130\u20134140","journal-title":"Vaccine"},{"key":"252_CR43","doi-asserted-by":"crossref","unstructured":"Mahairas GG et al (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178(5): 1274\u201382","DOI":"10.1128\/jb.178.5.1274-1282.1996"},{"issue":"4","key":"252_CR44","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaci.2014.02.028","volume":"133","author":"BE Marciano","year":"2014","unstructured":"Marciano BE et al (2014) BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol 133(4):1134\u20131141","journal-title":"J Allergy Clin Immunol"},{"key":"252_CR45","doi-asserted-by":"crossref","unstructured":"Mearns H et al (2017) H1:IC31 vaccination is safe and induces long-lived TNF-\u03b1(+)IL-2(+)CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial. Vaccine 35(1):132\u2013141","DOI":"10.1016\/j.vaccine.2016.11.023"},{"key":"252_CR46","doi-asserted-by":"crossref","unstructured":"Minassian AM et al (2011) Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PLoS One 6(5):e19840","DOI":"10.1371\/journal.pone.0019840"},{"issue":"7","key":"252_CR47","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/infdis\/jis012","volume":"205","author":"AM Minassian","year":"2012","unstructured":"Minassian AM et al (2012) A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis 205(7):1035\u20131042","journal-title":"J Infect Dis"},{"issue":"5","key":"252_CR48","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/infdis\/jiv482","volume":"213","author":"A Minhinnick","year":"2016","unstructured":"Minhinnick A et al (2016) Optimization of a human Bacille Calmette-Gu\u00e9rin challenge model: a tool to evaluate antimycobacterial immunity. J Infect Dis 213(5):824\u2013830","journal-title":"J Infect Dis"},{"issue":"3","key":"252_CR49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/infdis\/jiz138","volume":"220","author":"JI Moliva","year":"2019","unstructured":"Moliva JI et al (2019) The lung mucosa environment in the elderly increases host susceptibility to Mycobacterium tuberculosis infection. J Infect Dis 220(3):514\u2013523","journal-title":"J Infect Dis"},{"key":"252_CR50","doi-asserted-by":"crossref","unstructured":"Nemes E et al (2018) Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. New Engl J Med 379(2):138\u2013149","DOI":"10.1056\/NEJMoa1714021"},{"issue":"6","key":"252_CR51","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/infdis\/167.6.1481","volume":"167","author":"IM Orme","year":"1993","unstructured":"Orme IM, Andersen P, Boom WH (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167(6):1481\u20131497","journal-title":"J Infect Dis"},{"issue":"3","key":"252_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-2958.2002.03237.x","volume":"46","author":"AS Pym","year":"2002","unstructured":"Pym AS et al (2002) Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46(3):709\u2013717","journal-title":"Mol Microbiol"},{"issue":"5","key":"252_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym AS et al (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9(5):533\u2013539","journal-title":"Nat Med"},{"key":"252_CR54","doi-asserted-by":"crossref","unstructured":"Raviglione M, Scano F (2016) The 4th global forum on TB vaccines. Tuberculosis 99:S1eS2","DOI":"10.1016\/j.tube.2016.05.009"},{"key":"252_CR55","doi-asserted-by":"crossref","unstructured":"Redmann RK et al (2021) Particle dynamics and bioaerosol viability of aerosolized BCG vaccine using jet and vibrating mesh clinical nebulizers. bioRxiv 2021.04.26.441516","DOI":"10.1101\/2021.04.26.441516"},{"key":"252_CR56","doi-asserted-by":"crossref","unstructured":"Reither K et al (2014) Safety and immunogenicity of H1\/IC31\u00ae, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS One 9(12):e114602","DOI":"10.1371\/journal.pone.0114602"},{"issue":"10","key":"252_CR57","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","volume":"18","author":"M Roestenberg","year":"2018","unstructured":"Roestenberg M et al (2018) Experimental infection of human volunteers. Lancet Infect Dis 18(10):e312\u2013e322","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"252_CR58","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41385-019-0156-2","volume":"12","author":"JM Scordo","year":"2019","unstructured":"Scordo JM et al (2019) The human lung mucosa drives differential Mycobacterium tuberculosis infection outcome in the alveolar epithelium. Mucosal Immunol 12(3):795\u2013804","journal-title":"Mucosal Immunol"},{"issue":"1","key":"252_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1165\/rcmb.4840","volume":"29","author":"RF Silver","year":"2003","unstructured":"Silver RF et al (2003) Recruitment of antigen-specific Th1-like responses to the human lung following bronchoscopic segmental challenge with purified protein derivative of Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 29(1):117\u2013123","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"252_CR60","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrmicro1419","volume":"4","author":"YAW Skeiky","year":"2006","unstructured":"Skeiky YAW, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4(6):469\u2013476","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"252_CR61","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10156-013-0601-1","volume":"19","author":"JY Song","year":"2013","unstructured":"Song JY et al (2013) Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 19(3):412\u2013425","journal-title":"J Infect Chemother"},{"key":"252_CR62","doi-asserted-by":"crossref","unstructured":"Spencer CT et al (2013) Granzyme A produced by \u03b3(9)\u03b4(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathogens 9(1):e1003119","DOI":"10.1371\/journal.ppat.1003119"},{"issue":"12","key":"252_CR63","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","volume":"3","author":"F Spertini","year":"2015","unstructured":"Spertini F et al (2015) Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 3(12):953\u2013962","journal-title":"Lancet Respir Med"},{"key":"252_CR64","doi-asserted-by":"crossref","unstructured":"Steingart KR et al (2013) Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (1)","DOI":"10.1002\/14651858.CD009593.pub2"},{"key":"252_CR65","unstructured":"STOP TB Partnership U (2015) Global plan to end TB: The Paradigm Shift, 2016\u20132020. Geneva, Switzerland. http:\/\/www.stoptb.org\/assets\/documents\/global\/plan\/GlobalPlanToEndTB_TheParadigmShift_2016-2020_StopTBPartnership.pdf"},{"key":"252_CR66","doi-asserted-by":"crossref","unstructured":"Suliman S et al (2019) Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med 199(2): 220\u2013231","DOI":"10.1164\/rccm.201802-0366OC"},{"issue":"25","key":"252_CR67","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait DR et al (2019) Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis. N Engl J Med 381(25):2429\u20132439","journal-title":"N Engl J Med"},{"issue":"9871","key":"252_CR68","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris MD et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381(9871):1021\u20131028","journal-title":"Lancet"},{"issue":"9","key":"252_CR69","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","volume":"7","author":"M Tameris","year":"2019","unstructured":"Tameris M et al (2019) Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med 7(9):757\u2013770","journal-title":"Lancet Respir Med"},{"key":"252_CR70","doi-asserted-by":"crossref","unstructured":"Tkachuk AP et al (2020) Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines (Basel) 8(4)","DOI":"10.3390\/vaccines8040652"},{"issue":"2","key":"252_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1183\/09031936.00123314","volume":"45","author":"M Torres","year":"2015","unstructured":"Torres M et al (2015) Effect of isoniazid on antigen-specific interferon-\u03b3 secretion in latent tuberculosis. Eur Respir J 45(2):473\u2013482","journal-title":"Eur Respir J"},{"issue":"9","key":"252_CR72","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1086\/591974","volume":"47","author":"A Tostmann","year":"2008","unstructured":"Tostmann A et al (2008) Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 47(9):1135\u20131142","journal-title":"Clin Infect Dis"},{"issue":"20","key":"252_CR73","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","volume":"28","author":"JT van Dissel","year":"2010","unstructured":"van Dissel JT et al (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in na\u00efve human volunteers. Vaccine 28(20):3571\u20133581","journal-title":"Vaccine"},{"key":"252_CR74","doi-asserted-by":"crossref","unstructured":"Vasina DV et al (2019) First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment. Vaccines (Basel) 7(4)","DOI":"10.3390\/vaccines7040166"},{"issue":"43","key":"252_CR75","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1016\/j.vaccine.2014.08.009","volume":"32","author":"B Villarreal-Ramos","year":"2014","unstructured":"Villarreal-Ramos B et al (2014) Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle. Vaccine 32(43):5645\u20135649","journal-title":"Vaccine"},{"issue":"1","key":"252_CR76","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1165\/rcmb.2005-0060OC","volume":"33","author":"J Walrath","year":"2005","unstructured":"Walrath J et al (2005) Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 33(1):48\u201355","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"252_CR77","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1128\/CVI.00289-15","volume":"22","author":"AD White","year":"2015","unstructured":"White AD et al (2015) Evaluation of the immunogenicity of Mycobacterium bovis BCG delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol 22(9):992\u20131003","journal-title":"Clin Vaccine Immunol"},{"key":"252_CR78","unstructured":"WHO (2020) Global tuberculosis report 2020. Geneva"},{"key":"252_CR79","unstructured":"WHO (2016) Human challenge trials for vaccine development: regulatory considerations"},{"issue":"3","key":"252_CR80","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1086\/499311","volume":"193","author":"KA Wilkinson","year":"2006","unstructured":"Wilkinson KA et al (2006) Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193(3):354\u2013359","journal-title":"J Infect Dis"},{"issue":"5","key":"252_CR81","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1473-3099(19)30707-8","volume":"20","author":"CM Williams","year":"2020","unstructured":"Williams CM et al (2020) Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies. Lancet Infect Dis 20(5):607\u2013617","journal-title":"Lancet Infect Dis"},{"key":"252_CR82","doi-asserted-by":"crossref","unstructured":"Wong KW (2017) The Role of ESX-1 in Mycobacterium tuberculosis Pathogenesis. Microbiol Spectr 5(3)","DOI":"10.1128\/microbiolspec.TBTB2-0001-2015"},{"key":"252_CR83","doi-asserted-by":"crossref","unstructured":"Woodworth JS et al (2021) A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Gu\u00e9rin. bioRxiv 2021.03.18.435784","DOI":"10.1101\/2021.03.18.435784"},{"issue":"8","key":"252_CR84","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1080\/21645515.2019.1706930","volume":"16","author":"MA Yamazaki-Nakashimada","year":"2020","unstructured":"Yamazaki-Nakashimada MA et al (2020) BCG: a vaccine with multiple faces. Hum Vaccin Immunother 16(8):1841\u20131850","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"252_CR85","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1574-695X.2012.01002.x","volume":"66","author":"H Yang","year":"2012","unstructured":"Yang H, Kruh-Garcia NA, Dobos KM (2012) Purified protein derivatives of tuberculin\u2013past, present, and future. FEMS Immunol Med Microbiol 66(3):273\u2013280","journal-title":"FEMS Immunol Med Microbiol"}],"container-title":["Current Topics in Microbiology and Immunology","Human Challenge Studies for Vaccine Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2022_252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T12:03:17Z","timestamp":1729944197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2022_252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031631177","9783031631184"],"references-count":85,"URL":"https:\/\/doi.org\/10.1007\/82_2022_252","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"type":"print","value":"0070-217X"},{"type":"electronic","value":"2196-9965"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"25 March 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}